Regenxbio (RGNX) Non-Current Deffered Revenue (2015 - 2025)

Regenxbio (RGNX) recorded quarterly Non-Current Deffered Revenue of $18.9 million in Q4 2025, down 10.59% quarter-over-quarter from $21.2 million in Q3 2025.

Regenxbio (RGNX) Non-Current Deffered Revenue (2015 - 2025) Analysis & Trends

Regenxbio's Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $18.9 million for Q4 2025.

  • In Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $18.9 million; the TTM figure through Dec 2025 stood at $18.9 million (changed N/A YoY), while the FY2025 annual figure was $18.9 million, changed N/A from the prior year.
  • Non-Current Deffered Revenue was $18.9 million for Q4 2025 at Regenxbio, down from $21.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $26.3 million in Q1 2025 to a low of $3.5 million in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn -
9 Abivax 94.37 Bn 94.37 Bn - -
10 Regenxbio 315.11 Mn 85.04 Mn - 18.94 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 18.94 Mn
Sep 30, 2025 21.19 Mn
Jun 30, 2025 23.80 Mn
Mar 31, 2025 26.30 Mn
Sep 30, 2021 3.53 Mn
Jun 30, 2021 3.63 Mn
Mar 31, 2021 3.73 Mn
Dec 31, 2020 3.78 Mn
Sep 30, 2020 3.90 Mn
Jun 30, 2020 4.01 Mn
Mar 31, 2020 3.33 Mn
Dec 31, 2019 3.33 Mn
Sep 30, 2019 3.33 Mn
Jun 30, 2019 3.33 Mn
Mar 31, 2019 3.33 Mn
Dec 31, 2018 3.33 Mn
Sep 30, 2018 1.12 Mn
Jun 30, 2018 1.19 Mn
Mar 31, 2018 1.23 Mn
Dec 31, 2017 1.21 Mn